Phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma [abstract 7148] - Jackman,D.J.; Lucca,J.; Fidias,P. (Proc Am Soc Clin Oncol, 2005)